All In Biotech

Drug Trial Radar · NCT05380492

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Apr 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Nov 17, 2022

Primary completion

Nov 2025

Study completion Nov 2025

Sponsor

Lead sponsor
Perceive Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

Conditions

  • Age-related Macular Degeneration
  • Geographic Atrophy

Interventions

  • VOY-101Biological

    Intravitreal injection of VOY-101

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety EndpointsTime frame: Through 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Retina Consultants of Texas

    Bellaire, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.